BTS Group has signed an agreement to acquire all businesses

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
BTS Group has signed an agreement to acquire all businesses from The Synergy Group Pty Ltd.

Stockholm, Sweden and Sydney Australia, 2015-12-23 08:22 CET (GLOBE NEWSWIRE) --  

BTS GROUP AB (publ) – announced that it has signed an agreement to acquire all the businesses of The Synergy Group Pty Ltd. a leading Australian provider of sales transformation solutions, assessment, development services, and consulting services.

“The Synergy acquisition marks a natural extension of BTS’s sales transformation and assessment solutions. The acquisition opens new opportunities for both BTS and Synergy clients to accelerate their growth by improving their selling capabilities.” says Henrik Ekelund, President and CEO of BTS Group AB.

The Synergy Group CEO, Katherine Edgar says, “We are delighted to join forces with BTS. Transforming companies into world-class, high performing organizations is Synergy's reason for being, and we could not have hoped for a better partner than BTS to enable our vision.

The acquisition will significantly contribute to the BTS Australia business and will grow the size of the BTS Australia Sales Practice considerably. The additional resources will allow BTS to significantly increase our penetration of this key market. Synergy’s annual revenues is averaging AUD 3 million.

“BTS's strategy for acquisitions aims to create a broader base for future organic growth while actively consolidating a highly fragmented market. Through its acquisitions, BTS also seeks to gain the opportunity to serve new and existing customers with innovative services based on next-generation, innovative technologies and processes.” concludes Henrik Ekelund.

Information on the Transaction

About the acquisition, price and financing

BTS will acquire the business and key assets of The Synergy Group Systems Pty Ltd. including talent, technology, intellectual property, brands, and equipment, and assuming some liabilities.

Synergy will be consolidated as of December 1, 2015. The acquisition is estimated to have a positive impact on BTS earnings per share in 2016. No further financial facts are disclosed.

For more information, please contact:

Thomas Ahlerup

Senior Vice President

Financial Communications and Investor Relations

BTS Group AB

Phone               +46-8-5870 7002

Mobile               +46-768-966 300

E-mail               thomas.ahlerup@bts.com

About BTS Group AB

BTS is a global professional services firm headquartered in Stockholm, Sweden, with some 450 professionals in 33 offices located on six continents. We focus on the people side of strategy, working with leaders at all levels to help them make better decisions, convert those decisions to actions and deliver results. At our core, we believe people learn best by doing. For 30 years, we've been designing fun, powerful experiences that have a profound and lasting impact on people and their careers. We inspire new ways of thinking, build critical capabilities and unleash business success. It’s strategy made personal.

We serve a wide range of strategy execution and talent development needs. Our services span the employee lifecycle from assessment centers for talent selection and development to strategy alignment and execution initiatives, and from business acumen, leadership and sales training programs to on-the-job business simulations and application tools. We partner with nearly 450 organizations, including over 30 of the world’s 100 largest global corporations. Our major clients are some of the most respected names in business: AT&T, Chevron, Coca-Cola, Ericsson, Google, GSK, HP, HSBC, Salesforce.com, Telstra, and Unilever.

BTS is a public company listed on the NASDAQ Stockholm and trades under the symbol BTS B.

For more information, please visit www.bts.com.

About The Synergy Group Pty Ltd.

The Synergy Group, founded in 1998 and headquartered in Sydney, is a premier provider of sales transformation solutions, assessment, development services, and consulting services. The Synergy Group offers a proven and sustainable scientifically based methodology and approach to transform their clients’ sales organizations, predict sales potential, and accelerate performance. Synergy was one of the first firms in Australia to offer the use of assessment and benchmarking services to predict the performance of sales professionals and sales leaders.

Synergy has developed a strong Australian market position, with a multi-lingual delivery capability that spans the Asia Pacific region. Key focus areas include banking and finance, professional services, and information technology and telecommunications industries. Their client list includes many of the region’s leading businesses.

Disclaimer: Every care has been taken in the translation of this press release. In the event of discrepancies, however, the Swedish original will supersede the English translation. This information has been disclosed according to the Financial Instruments Trading Act and/or Securities Trading Act.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 35

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 37

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 31

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 34

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Bank of Canada Considers Interest Rate Cuts Amid Growth Concerns

Updated Category News Views 91

Bank of Canada Considers Possible Rate Cuts Recent discussions reported by the Financial Times reveal that Governor Tiff Macklem of the Bank of Canada has started exploring the possibility of increasing the pace at which interest rates could be cut. This potential shift highlights the Bank's response to growing concerns about the Canadian economy's current dynamics....

Continue Reading
Photonics Market Poised for Massive Growth by 2030

Updated Category News Views 151

Understanding the Photonics Market Growth The photonics industry is on an impressive trajectory, with projections indicating it will grow significantly over the coming years. Experts foresee the market expanding from approximately USD 1,093.96 billion to an astounding USD 1,481.80 billion by 2030, reflecting a compound annual growth rate (CAGR) of around 6.3%. This rapid...

Continue Reading
Brookfield Infrastructure Plans Redemption of Preferred Units

Updated Category News Views 154

Brookfield Infrastructure Announces Series 3 Redemption Plan BROOKFIELD, News - Brookfield Infrastructure Partners L.P. (TSX: BIP.UN; NYSE: BIP) has announced its intention to redeem all outstanding Cumulative Class A Preferred Limited Partnership Units, Series 3 (the “Series 3 Preferred Units”). This strategic decision aims to enhance their portfolio's financial...

Continue Reading
How a $1000 Investment in Enphase Energy Grew to $3200

Updated Category News Views 147

Transforming $1000 into $3200 with Enphase Energy Investing can be a journey filled with uncertainties, but the story of Enphase Energy (NASDAQ: ENPH) reveals a powerful lesson in the potential of financial growth. Over the past five years, Enphase Energy has impressively outperformed many market benchmarks, achieving a remarkable annualized return of 26.49%. At present,...

Continue Reading
Investors Should Pay Attention: Rocket Pharmaceuticals Lawsuit Update

Updated Category News Views 191

The Class Action Lawsuit Against Rocket Pharmaceuticals Recently, investors of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) have been advised to participate in a class action lawsuit for potential securities fraud. This lawsuit arises from significant concerns over the company's disclosure practices and the impact of leadership decisions on stock performance. If you are an...

Continue Reading